IMVT – Immunovant Inc
IMVT — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
19.71
Margin Of Safety %
Put/Call OI Ratio
0.16
EPS Next Q Diff
-0.2
EPS Last/This Y
0.2
EPS This/Next Y
-0.09
Price
23.97
Target Price
40.35
Analyst Recom
1.56
Performance Q
-10.79
Upside
-245.3%
Beta
0.66
Ticker: IMVT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | IMVT | 26.42 | 0.08 | 0.26 | 29389 |
| 2026-03-10 | IMVT | 25.73 | 0.08 | 0.00 | 29371 |
| 2026-03-11 | IMVT | 25.56 | 0.09 | 0.09 | 27593 |
| 2026-03-12 | IMVT | 25.01 | 0.09 | 0.04 | 27594 |
| 2026-03-13 | IMVT | 24.99 | 0.09 | 0.04 | 27594 |
| 2026-03-17 | IMVT | 25.1 | 0.09 | 0.14 | 28530 |
| 2026-03-18 | IMVT | 23.58 | 0.09 | 0.03 | 28635 |
| 2026-03-19 | IMVT | 23.62 | 0.09 | 0.40 | 28812 |
| 2026-03-20 | IMVT | 23.01 | 0.09 | 0.48 | 28820 |
| 2026-03-23 | IMVT | 24.39 | 0.08 | 0.17 | 28030 |
| 2026-03-24 | IMVT | 23.84 | 0.08 | 0.43 | 28065 |
| 2026-03-25 | IMVT | 24.73 | 0.11 | 11.73 | 31291 |
| 2026-03-26 | IMVT | 25.34 | 0.16 | 0.07 | 32721 |
| 2026-03-27 | IMVT | 23.98 | 0.16 | 0.10 | 32702 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | IMVT | 26.40 | 12.2 | 48.1 | -2.52 |
| 2026-03-10 | IMVT | 25.73 | 12.2 | 56.3 | -2.52 |
| 2026-03-11 | IMVT | 25.53 | 12.2 | 46.9 | -2.52 |
| 2026-03-12 | IMVT | 25.01 | 12.2 | 54.2 | -2.52 |
| 2026-03-13 | IMVT | 24.41 | 12.2 | 55.2 | -2.52 |
| 2026-03-17 | IMVT | 25.10 | 12.2 | 41.0 | -2.52 |
| 2026-03-18 | IMVT | 23.59 | 12.2 | 75.4 | -2.52 |
| 2026-03-19 | IMVT | 23.62 | 12.2 | 74.8 | -2.52 |
| 2026-03-20 | IMVT | 22.98 | 12.2 | 87.9 | -2.52 |
| 2026-03-23 | IMVT | 24.35 | 12.2 | 59.8 | -2.52 |
| 2026-03-24 | IMVT | 23.85 | 12.2 | 69.9 | -2.53 |
| 2026-03-25 | IMVT | 24.75 | 12.2 | 51.6 | -2.53 |
| 2026-03-26 | IMVT | 25.38 | 12.2 | 38.8 | -2.53 |
| 2026-03-27 | IMVT | 23.97 | 12.2 | 67.7 | -2.53 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-06 | IMVT | 16.12 | 5.64 | 20.17 |
| 2026-03-09 | IMVT | 16.12 | 5.74 | 20.17 |
| 2026-03-10 | IMVT | 16.12 | 5.74 | 20.17 |
| 2026-03-11 | IMVT | 16.12 | 5.74 | 20.03 |
| 2026-03-12 | IMVT | 16.12 | 5.74 | 20.03 |
| 2026-03-13 | IMVT | 16.12 | 5.74 | 20.03 |
| 2026-03-17 | IMVT | 16.12 | 5.74 | 20.03 |
| 2026-03-18 | IMVT | 16.12 | 5.74 | 20.03 |
| 2026-03-19 | IMVT | 16.12 | 5.74 | 20.03 |
| 2026-03-20 | IMVT | 16.12 | 5.74 | 20.03 |
| 2026-03-23 | IMVT | 16.12 | 5.74 | 20.03 |
| 2026-03-24 | IMVT | 16.12 | 5.74 | 20.03 |
| 2026-03-25 | IMVT | 16.12 | 5.74 | 19.71 |
| 2026-03-26 | IMVT | 16.12 | 5.74 | 19.71 |
| 2026-03-27 | IMVT | 16.12 | 5.74 | 19.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.61
Avg. EPS Est. Current Quarter
-0.56
Avg. EPS Est. Next Quarter
-0.81
Insider Transactions
16.12
Institutional Transactions
5.74
Beta
0.66
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
18
Sentiment Score
73
Actual DrawDown %
47.4
Max Drawdown 5-Year %
-79.9
Target Price
40.35
P/E
Forward P/E
PEG
P/S
P/B
4.94
P/Free Cash Flow
EPS
-2.68
Average EPS Est. Cur. Y
-2.53
EPS Next Y. (Est.)
-2.62
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.81
Return on Equity vs Sector %
-74.4
Return on Equity vs Industry %
-58.2
EPS 1 7Days Diff
EPS 1 30Days Diff
0.06
EBIT Estimation
67.7
◆
IMVT
Healthcare
$23.98
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
42.5
Range 1M
24.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
3.5%
EPS NY
2.3%
52W%
69%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+68.3% upside
Upside
+68.3%
Quality
9
Immunovant, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 362
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT
Latest News
—
Caricamento notizie per IMVT…
stock quote shares IMVT – Immunovant Inc Stock Price stock today
news today IMVT – Immunovant Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch IMVT – Immunovant Inc yahoo finance google finance
stock history IMVT – Immunovant Inc invest stock market
stock prices IMVT premarket after hours
ticker IMVT fair value insiders trading